Related Experiment Videos
VS38 immunostaining in neuroendocrine tumours
S S Banerjee1, J H Shanks, P S Hasleton
1Department of Histopathology, Christie Hospital NHS Trust, Manchester, UK.
Histopathology
|March 1, 1997
Summary
The antibody VS38, initially a plasma cell marker, also reacts with neuroendocrine tumors. Awareness of VS38
Area of Science:
- Oncology
- Immunohistochemistry
- Pathology
Background:
- VS38 antibody was initially identified as a marker for neoplastic and non-neoplastic plasma cells.
- Recent studies have shown its immunoreactivity with melanocytic lesions.
- The specificity of VS38 in various tumor types requires further investigation.
Purpose of the Study:
- To investigate the reactivity of the VS38 antibody with a diverse range of neuroendocrine tumors.
- To assess the utility of VS38 as a potential marker in the diagnosis of neuroendocrine neoplasms.
- To understand the implications of VS38's reactivity in differential diagnosis.
Main Methods:
- Immunohistochemical analysis of VS38 expression.
- Utilized paraffin-embedded tissue sections from archival samples.
- Tested VS38 reactivity across a spectrum of 50 neuroendocrine tumors.
Main Results:
- 72% of the tested neuroendocrine tumors (36 out of 50) exhibited immunohistochemical positivity for VS38.
- A broad range of neuroendocrine tumor subtypes demonstrated reactivity with the VS38 antibody.
- The findings indicate a lack of specificity for VS38 in distinguishing neuroendocrine tumors from other entities.
Conclusions:
- VS38 demonstrates reactivity across a wide spectrum of neuroendocrine tumors.
- The lack of specificity of VS38 necessitates the use of a panel of markers for accurate diagnosis.
- Awareness of VS38's reactivity is crucial to avoid misdiagnosis, especially in unusual tumor locations or presentations.